Last January, Europe’s carmakers were gearing up for their most challenging year in recent memory — one in which they would be forced to vastly expand their sales of electric and hybrid cars or fall foul of tough new emissions regulations and risk hundreds of millions of euros in fines. Then came Covid-19, and lockdowns that brought assembly lines to a standstill for weeks, delaying for several months the rollout of key emissions-free models, such as Volkswagen’s flagship ID. Of the nearly 730,000 battery electric vehicles sold in western Europe during 2020, over 300,000 were delivered in the last three months of the year, according to research by Bernstein.
Rural communities have suffered a steep rise in hare coursing, with the RSPCA saying the growing involvement of gangs in wildlife crimes is a major factor in its decision to hand over its 200-year-old prosecuting powers to the CPS. Dozens of rural landowners are being repeatedly targeted by gangs who gather to bet on the outcome of dogs chasing down and killing as many hares as possible. Latest figures obtained by The Telegraph show that in some counties, such as North Yorkshire, there was a 51 per cent increase in incidents of hare coursing and poaching last year. A similar increase is expected this year. The RSPCA’s chief executive, Chris Sherwood, said on Saturday: “We’re involved in cases that involve cock fighting, badger baiting and hare coursing, which can involve millions of pounds of fraud, tax evasion and even weapons and these cases are complex. “We think there’s a better way for us which is to mirror the situation in Scotland, where our sister charity, the SSPCA, transfers its cases and files over to the procurator fiscal, the Scottish equivalent of the CPS, so there’s that division between investigation and prosecution.”
It's no secret that we need several companies' products to gain approval in order to meet worldwide demand for a coronavirus vaccine. Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) reached commercialization first when the U.S. Food and Drug Administration (FDA) granted their vaccine candidates Emergency Use Authorization (EUA) late last year. Johnson & Johnson (NYSE: JNJ), AstraZeneca (NASDAQ: AZN), and Novavax (NASDAQ: NVAX) are close behind.